Examining von Willebrand Disease Treatment and the Role of Specialty Pharmacy Services

Examining von Willebrand Disease Treatment and the Role of Specialty Pharmacy Services is organized by Pharmacy Times Continuing Education (PTCE)

Release Date: June 5, 2019
Expiration Date: June 5, 2020

Target Audience: 
Specialty Pharmacists and Managed Care Professionals.

Accreditation:
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs)

Activity Overview:
Von Willebrand disease (VWD) is the most common bleeding disorder, affecting up to 1% of the population worldwide, and is caused by the absence of, reduced amounts of, or defects in von Willebrand factor (VWF). Human plasma-derived VWF concentrates containing varying amounts of VWF multimer distribution and factor VIII (FVIII) content have been available for decades. A recombinant VWF eliminates the need for human donors, decreases the risk for any infectious transfers, and minimizes the thrombosis risk due to the absence of FVIII. Specialty pharmacists should know how to tailor these therapies for specific patients’ needs. Effective interventions will maximize quality of life, reduce hospitalizations and emergency department visits, optimize health care utilization, and effectively manage bleeding risk and adverse events during disease management.

Educational Objectives:
At the completion of this activity, the participant will be able to:
• Determine the classifications of VWD and their impact to patient care
• Analyze the data of FDA-approved VWD factors and identify their role in therapy
• Examine practices for managing the cost and availability of VWD treatments

Additional details will be posted as soon as information is available.